Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Core Insights - Can-Fite BioPharma Ltd. is hosting a webinar on February 25, 2025, to discuss its development pipeline and milestones [1][2] - The company has multiple out-licensing deals and potential regulatory and sales milestone payments exceeding $130 million, with $20 million already received [2] - Can-Fite's advanced-stage assets target unmet medical needs in markets valued over $70 billion, positioning the company for potential commercialization [2] Company Overview - Can-Fite BioPharma Ltd. is focused on developing small molecule drugs for oncological and inflammatory diseases, with a lead drug candidate, Piclidenoson, recently reporting Phase III trial results for psoriasis [4] - The company is also evaluating Namodenoson in various trials, including a Phase IIb for Metabolic Dysfunction-associated Steatohepatitis (MASH) and a Phase III for hepatocellular carcinoma (HCC) [4] - Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for HCC treatment [4] - CF602, another drug candidate, has shown efficacy in treating erectile dysfunction, with all drugs demonstrating a strong safety profile in over 1,600 patients [4]